Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as part of this Annual Report:

Financial Statements.

The consolidated financial statements listed in Part II, Item 8 of this Annual Report.

Financial Statement Schedules.

For the three fiscal years ended December 31, 2021, Schedule II – Valuation and Qualifying Accounts.

Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.

Exhibits.


Exhibit Number	Exhibit Description	Incorporated by Reference				Provided Herewith
Form	File No.	Date of First Filing	Exhibit Number


3.01	Restated Certificate of Incorporation of Dexcom, Inc.	8-K	000-51222	May 21, 2021	3.1
3.02	Amended and Restated Bylaws of DexCom, Inc.	8-K	000-51222	May 21, 2021	3.3

4.01	Form of Specimen Certificate for Registrant’s common stock	S-1/A	333-122454	March 24, 2005	4.01
4.02	Indenture, dated as of November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023)	8-K	000-51222	December 3, 2018	4.1
4.03	Indenture, dated as of May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due 2025)	8-K	000-51222	May 15, 2020	4.1
4.04	Description of Securities Registered Under Section 12 of the Exchange Act.	10-K	000-51222	February 11, 2021	4.04
10.01	Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P.	8-K	000-51222	April 7, 2006	99.01




10.02	First Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated August 18, 2010.	10-Q	000-51222	November 4, 2010	10.27
10.03	Amendment Number One to Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated March 29, 2011.**	10-Q/A	000-51222	July 1, 2011	10.26
10.04	Offer letter between DexCom, Inc. and Kevin Sayer dated May 3, 2011.*	10-Q	000-51222	August 3, 2011	10.28
10.05	Amendment Number Two to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated March 28, 2013.**	10-Q	000-51222	May 1, 2013	10.27
10.06	Amendment Number Three to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated December 4, 2013.**	10-K	000-51222	February 20, 2014	10.28


Exhibit Number	Exhibit Description	Incorporated by Reference				Provided Herewith
Form	File No.	Date of First Filing	Exhibit Number
10.07	Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC dated October 12, 2009, as amended on September 30, 2010, October 11, 2011, November 14, 2012 and November 1, 2013.**	10-K	000-51222	February 20, 2014	10.29

10.08	Amendment No. 5 to Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC, dated March 14, 2014.	10-Q	000-51222	August 6, 2014	10.32
10.09	Second Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated October 1, 2014.	10-K	000-51222	February 25, 2015	10.32
10.10	2015 Employee Stock Purchase Plan	DEF 14A	000-51222	April 13, 2015	Appendix B
10.11	Form of Subscription Agreement under 2015 Employee Stock Purchase Plan	8-K	000-51222	June 2, 2015	10.4
10.12	Sublease between DexCom, Inc. and Entropic Communications, LLC dated February 1, 2016.	10-Q	000-51222	April 27, 2016	10.36
10.13	Amended and Restated Non-Exclusive Distribution Agreement with Byram Healthcare dated February 1, 2016.**	10-Q	000-51222	April 27, 2016	10.37
10.14	Industrial Net Lease, Broadway dated April 28, 2016, by and between PRA/LB, L.L.C. and DexCom, Inc.	10-Q	000-51222	August 2, 2016	10.39
10.15	Standard Form of Agreement dated May 2, 2016, by and between DexCom, Inc. and Skanska USA Building Inc.	10-Q	000-51222	August 2, 2016	10.40
10.16	Amendment to Non-Exclusive Distribution Agreement dated April 30, 2016 by and between RGH Enterprises, Inc. d/b/a Cardinal Health at Home and DexCom, Inc. **	10-Q	000-51222	August 2, 2016	10.41
10.17	Amendment No. 1 to Collaboration and License Agreement dated October 25, 2016 by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).	10-K	000-51222	February 28, 2017	10.42
10.18	Severance and Change in Control Plan.	8-K	000-51222	June 6, 2017	10.2
10.19	Form of Participation Agreement to the Severance and Change in Control Plan.	8-K	000-51222	June 6, 2017	10.3

10.20	Standard Form of Agreement dated May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.	10-Q	000-51222	August 1, 2017	10.47
10.21	Form of Indemnity Agreement	10-Q	000-51222	August 1, 2017	10.43
10.22	Form of RSU Grant Agreement 2015 Plan Global Double Trigger	10-K	000-51222	February 27, 2018	10.51
10.23	Form of RSU Grant Agreement 2015 Plan Global General	10-K	000-51222	February 27, 2018	10.52
10.24	Amended and Restated Collaboration and License Agreement dated November 20, 2018 by and between DexCom, Inc., Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited.**	10-K	000-51222	February 21, 2019	10.60


Exhibit Number	Exhibit Description	Incorporated by Reference				Provided Herewith
Form	File No.	Date of First Filing	Exhibit Number
10.25	Amended and Restated Credit Agreement dated December 19, 2018 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.	10-K	000-51222	February 21, 2019	10.61
10.26	Amended and Restated 2015 Equity Incentive Plan	8-K	000-51222	June 4, 2019	10.01
10.27	Executive Deferred Compensation Plan	8-K	000-51222	June 4, 2019	10.02
10.28	Form of RSU Grant Agreement 2015 Plan (Board Members - Annual Grant)	10-K	000-51222	February 13, 2020	10.36
10.29	Form of RSU Grant Agreement 2015 Plan (Board Members - Incoming Grant)	10-K	000-51222	February 13, 2020	10.37
10.30	Distribution Services Agreement dated November 7, 2015 between DexCom, Inc. and AmerisourceBergen Drug Corporation.****	10-K	000-51222	February 13, 2020	10.38
10.31	Amendment to the Distribution Services Agreement between DexCom Inc. and AmerisourceBergen Drug Corporation.****	10-K	000-51222	February 13, 2020	10.39
10.32	Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019.****	10-K	000-51222	February 13, 2020	10.40
10.33	Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019.****	10-K	000-51222	February 13, 2020	10.41
10.34	Fifth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated October 21, 2019.	10-K	000-51222	February 13, 2020	10.42

10.35	Form of Indemnity Agreement between Registrant and each of its directors and executive officers.	10-K	000-51222	February 11, 2021	10.43
10.36	2015 Employee Stock Purchase Plan, amended on December 13, 2019	10-K	000-51222	February 11, 2021	10.44
10.37	Form of Subscription Agreement under 2015 Employee Stock Purchase Plan amended on December 13, 2019	10-K	000-51222	February 11, 2021	10.45


10.38	DexCom Incentive Bonus Plan	8-K	000-51222	March 17, 2021	10.1
10.39	Second Amended and Restated Credit Agreement dated October 13, 202 1 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.	10-K	000-51222	February 14, 2022		X
10.40	Sixth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated May 25, 2021	10-K	000-51222	February 14, 2022		X
10.41	Tenant Estoppel Certificate - Sequence	10-K	000-51222	February 14, 2022		X
10.42	Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated January 31, 2020	10-K	000-51222	February 14, 2022		X
10.43	First Amendment to Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated November 17, 2020	10-K	000-51222	February 14, 2022		X
10.44	Tenant Estoppel Certificate - Pacific Center	10-K	000-51222	February 14, 2022		X


Exhibit Number	Exhibit Description	Incorporated by Reference			Provided Herewith
Form	File No.	Date of First Filing	Exhibit Number
10.45	Tenant’s Acceptance of Possession - Pacific Center	10-K	000-51222	February 14, 2022	X
21.01	List of Subsidiaries				X
23.01	Consent of Independent Registered Public Accounting Firm				X
24.01	Power of Attorney (see signature page of this Form 10-K)				X
31.01	Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).				X
31.02	Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).				X
32.01	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).***				X
32.02	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).***				X
101.INS	Inline XBRL Instance Document				X
101.SCH	Inline XBRL Taxonomy Extension Schema Document				X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				X
—	Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)				X


*			Represents a management contract or compensatory plan.
**			Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and were filed separately with the Securities and Exchange Commission.
***			This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference.
****			Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

Previous: Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES · Next: Item 16. FORM 10-K SUMMARY